Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Other Non-Current Assets (2019 - 2025)

C4 Therapeutics (CCCC) has 7 years of Other Non-Current Assets data on record, last reported at $3.7 million in Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 6.97% year-over-year to $3.7 million; the TTM value through Dec 2025 reached $3.7 million, up 6.97%, while the annual FY2025 figure was $3.7 million, 6.97% up from the prior year.
  • Other Non-Current Assets reached $3.7 million in Q4 2025 per CCCC's latest filing, up from $3.4 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $3.7 million in Q4 2025 and bottomed at $1.3 million in Q2 2021.
  • Average Other Non-Current Assets over 5 years is $3.1 million, with a median of $3.4 million recorded in 2021.
  • Peak YoY movement for Other Non-Current Assets: tumbled 50.49% in 2021, then skyrocketed 156.97% in 2022.
  • A 5-year view of Other Non-Current Assets shows it stood at $3.3 million in 2021, then changed by 0.0% to $3.3 million in 2022, then increased by 5.0% to $3.4 million in 2023, then changed by 0.0% to $3.4 million in 2024, then rose by 6.97% to $3.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $3.7 million in Q4 2025, $3.4 million in Q3 2025, and $3.4 million in Q2 2025.